G1 Therapeutics Inc. (NASDAQ: GTHX) stock jumped 4.19% on Friday to $6.47 against a previous-day closing price of $6.21. With 0.59 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.18 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.47 whereas the lowest price it dropped to was $6.20. The 52-week range on GTHX shows that it touched its highest point at $17.49 and its lowest point at $3.84 during that stretch. It currently has a 1-year price target of $29.57. Beta for the stock currently stands at 1.62.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GTHX was up-trending over the past week, with a rise of 8.01%, but this was up by 10.98% over a month. Three-month performance dropped to -37.61% while six-month performance fell -23.97%. The stock lost -28.67% in the past year, while it has gained 19.15% so far this year. A look at the trailing 12-month EPS for GTHX yields -3.61 with Next year EPS estimates of -2.91. For the next quarter, that number is -0.82. This implies an EPS growth rate of -35.00% for this year and 16.40% for next year.
Float and Shares Shorts:
At present, 50.60 million GTHX shares are outstanding with a float of 46.49 million shares on hand for trading. On Oct 13, 2022, short shares totaled 7.04 million, which was 16.46% higher than short shares on Sep 14, 2022. In addition to Mr. John E. Bailey Jr. as the firm’s CEO, Pres & Director, Ms. Jennifer K. Moses CPA serves as its Chief Financial Officer.
Through their ownership of 54.00% of GTHX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 28.13% of GTHX, in contrast to 27.19% held by mutual funds. Shares owned by individuals account for 15.93%. As the largest shareholder in GTHX with 5.80% of the stake, Fisher Asset Management LLC holds 2,935,332 shares worth 2,935,332. A second-largest stockholder of GTHX, JPMorgan Investment Management, I, holds 2,045,814 shares, controlling over 4.04% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in GTHX, holding 1,674,565 shares or 3.31% stake. With a 2.56% stake in GTHX, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 1,295,502 shares are owned by the mutual fund manager. The JPMorgan Small Cap Growth Fund, which owns about 2.40% of GTHX stock, is the second-largest Mutual Fund holder. It holds 1,214,990 shares valued at 6.6 million. LO Selection – NextGen BioTech holds 1.90% of the stake in GTHX, owning 961,139 shares worth 5.22 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GTHX since 8 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 2 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With GTHX analysts setting a high price target of $51.00 and a low target of $7.00, the average target price over the next 12 months is $29.57. Based on these targets, GTHX could surge 688.25% to reach the target high and rise by 8.19% to reach the target low. Reaching the average price target will result in a growth of 357.03% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. GTHX will report FY 2022 earnings on 02/21/2024. Analysts have provided yearly estimates in a range of -$3.30 being high and -$3.58 being low. For GTHX, this leads to a yearly average estimate of -$3.48. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. G1 Therapeutics Inc. surprised analysts by $0.05 when it reported -$0.59 EPS against a consensus estimate of -$0.64. The surprise factor in the prior quarter was $0.10. Based on analyst estimates, the high estimate for the next quarter is -$0.68 and the low estimate is -$0.92. The average estimate for the next quarter is thus -$0.82.
Summary of Insider Activity:
Insiders traded GTHX stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 14,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 14 while that of sell transactions has risen to 6 over the past year. The total number of shares bought during that period was 224,333 while 134,296 shares were sold.